APYX MEDICAL CORPORATION Company News: Berger Montague Investigates Securities Fraud Allegations Against Apyx Medical Corp. (APYX); Lead Plaintiff Deadline is August 5, 2022

Philadelphia, Pennsylvania--(Newsfile Corp. - July 1, 2022) - Berger Montague is investigating securities fraud allegations on behalf of investors who purchased the securities Apyx Medical Corporation ("Apyx" or the "Company") (NASDAQ: APYX) between May 12, 2021 and March 11, 2022 (the "Class Period").

If you purchased the securities of Apyx during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Michael Dell'Angelo at mdellangelo@bm.net or (215) 875-3080 or visit: https://investigations.bergermontague.com/apyx-medical-/.

Whistleblowers: Anyone with non-public information regarding Apyx is encouraged to confidentially assist Berger Montague's investigation or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.

On March 14, 2022, Apyx disclosed that the U.S. Food and Drug Administration (FDA) would be posting a Medical Device Safety Communication (MDSC) related to the Company's Advanced Energy Products. The Company further disclosed that "[b]ased on our initial interactions with the FDA, we believe the Agency's MDSC will pertain to the use of our Advanced Energy products outside of their FDA-cleared indication for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures."

On this news, Apyx's stock fell $4.02, or 40.6%, to close at $5.88 per share on March 14, 2022, on unusually heavy trading volume.

The complaint filed in this class action alleges that throughout the Class Period, Defendants misled investors about the fact that: (1) a significant number of Apyx's Advanced Energy products were used for off-label indications; and (2) such off-label uses led to an increase in the number of medical device reports filed by Apyx reporting serious adverse events.

Berger Montague, with offices in Philadelphia, Minneapolis, Washington, D.C., and San Diego, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bm.net

Michael Dell'Angelo, Executive Shareholder
Berger Montague
(215) 875-3080
mdellangelo@bm.net

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129745

info